Samer A Srour, MB ChB, MS

Peer-Reviewed Articles

1. Srour SA, Olson A, Ciurea SO, Desai P, Bashir Q, Oran B, Bose P, Mehta R, Patel KP, Pemmaraju N, Daver N, Verstovsek S, Champlin RE, Popat UR. Mixed myeloid chimerism and relapse of myelofibrosis after allogeneic stem cell transplantation. Haematologica 106(7):1988-1990, 2021. e-Pub 2021. PMID: 31296578.
2. Olson AL, Saliba RM, Oran B, Chen J, Alousi A, Ahmed S, Bashir Q, Ciurea SO, Hosing C, Seon Im J, Kebriaei P, Khouri IF, Mehta R, Nieto Y, Parmar S, Rezvani K, Shah N, Shpall E, Srour SA, Qazilbash M, Andersson BS, Champlin R, Popat UR. Cytogenetics and Blast Count Determine Transplant Outcomes in Patients with Active Acute Myeloid Leukemia. Acta Haematol 144(1):74-81, 2021. e-Pub 2020. PMID: 32604096.
3. Srour SA, Saliba RM, Bittencourt MCB, Perez JMR, Kongtim P, Alousi A, Al-Atrash G, Olson A, Betul O, Mehta R, Popat U, Hosing C, Bashir Q, Khouri I, Kebriaei P, Masarova L, Short N, Jabbour E, Daver N, Konopleva M, Ravandi F, Kantarjian H, Champlin RE, Ciurea SO. Haploidentical transplantation for acute myeloid leukemia patients with minimal/measurable residual disease at transplantation. Am J Hematol 94(12):1382-1387, 2019. e-Pub 2019. PMID: 31595538.
4. Kongtim P, Hasan O, Perez JMR, Varma A, Wang SA, Patel KP, Chen J, Rondon G, Srour S, Bashir Q, Qazilbash M, Mehta R, Shpall EJ, Alousi A, Khouri I, Kebriaei P, Popat U, Champlin RR, Ciurea SO. A Novel Disease Risk Model for Patients with AML Receiving Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. e-Pub 2019. PMID: 31518645.
5. Saini NY, Ma J, Milton DR, Patel RD, Varma A, Bashir Q, Delgado RE, Tang G, Rondon G, Popat U, Hosing C, Nieto Y, Kebriaei P, Alousi A, Ahmed S, Mehta R, Srour S, Khouri IF, Iyer S, Weber D, Thomas SK, Lee HC, Manasanch EE, Patel K, Orlowski RZ, Champlin RE, Qazilbash MH. Impact of autologous transplantation in multiple myeloma patients with t(11;14): a propensity-score matched analysis. Clin Cancer Res. e-Pub 2019. PMID: 31481508.
6. van Besien K, Artz A, Champlin RE, Guarneri D, Bishop MR, Chen J, Gergis U, Shore T, Liu H, Rondon G, Mayer SA, Srour SA, Stock W, Ciurea SO. Haploidentical vs haplo-cord transplant in adults under 60 years receiving fludarabine and melphalan conditioning. Blood Adv 3(12):1858-1867, 2019. PMID: 31217161.
7. Maymani H, Lin P, Saliba RM, Popat U, Bashir Q, Shah N, Patel K, Parmar S, Kebriaei P, Hosing C, Ciurea S, Andersson B, Shpall E, Champlin R, Srour SA, Qazilbash MH. Comparison of Outcomes of Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Three Different Conditioning Regimens. Biol Blood Marrow Transplant 25(5):1039-1044, 2019. e-Pub 2019. PMID: 30639822.
8. Mehta RS, Bassett R, Olson A, Chen J, Ahmed S, Alousi AM, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Kebriaei P, Khouri I, Marin D, Molldrem JJ, Nieto Y, Oran B, Rezvani K, Qazilbash MH, Srour SA, Shpall EJ, Andersson BS, Champlin RE, Popat UR. Myeloablative conditioning using timed-sequential busulfan plus fludarabine in older patients with acute myeloid leukemia: long term results of a prospective phase II clinical trial. Haematologica. e-Pub 2019. PMID: 30948491.
9. Ibrahimi S, Mukherjee S, Machiorlatti MG, Maymani H, Vesely SK, Srour SA, Cherry M.. Effect of time of admission to treatment initiation on outcomes of patients with acute myeloid leukemia: a tertiary care referral center experience. J Community Support Oncol 16(5):e188-e93, 2018.